entity,start_date,end_date,context,AARSRAPPORT_pdf,AARSRAPPORT_xml,AddressOfAuditorCountry,AddressOfAuditorPostcodeAndTown,AddressOfAuditorStreetAndNumber,AddressOfReportingEntityPostcodeAndTown,AddressOfReportingEntityStreetAndNumber,AddressOfSubmittingEnterprisePostcodeAndTown,AddressOfSubmittingEnterpriseStreetAndNumber,AddresseeOfAuditorsReportOnAuditedFinancialStatements,ClassOfReportingEntity,ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement,ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults,DateOfApprovalOfAnnualReport,DateOfApprovalOfReport,DateOfGeneralMeeting,DescriptionOfMemberOfSupervisoryBoardApprovingStatementOfExecutiveAndSupervisoryBoard,DescriptionOfMethodsOfAmortisationOfNoncurrentAssets,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAdministrativeExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables,DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod,DescriptionOfSpecificRisksInAdditionToCommonlyOccurringHazardsInIndustry,DisclosureOfDepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss,DisclosureOfOtherOperatingExpenses,DisclosureOfProvisionsForDeferredTax,Equity,ExplanationOfNotDisclosingCashFlowsStatements,ExplanationOfOtherMethodsOfRecognitionAndMeasurementBasisForAssetsInPreviousPeriod,ExtraordinaryDividendPaid,FaxNumberOfReportingEntity,HomepageOfReportingEntity,IdentificationNumberCvrOfReportingEntity,IdentificationNumberCvrOfSubmittingEnterprise,IdentificationOfApprovedAnnualReport,IdentificationOfAuditedFinancialStatements,IncreaseDecreaseOfIntangibleAssetsThroughTransfers,InformationOnRemunerationOfManagementCategoriesAndSpecialIncentiveProgrammes,InformationOnReportingClassOfEntity,InformationOnSegments,InformationOnTypeOfSubmittedReport,ManagementsStatementAboutManagementsReview,NameAndSurnameOfChairmanOfGeneralMeeting,NameAndSurnameOfMemberOfExecutiveBoard,NameOfReportingEntity,NameOfSubmittingEnterprise,OpinionOnAuditedFinancialStatements,PlaceOfSignatureOfStatement,RecommendationForApprovalOfAnnualReportByGeneralMeeting,RegisteredOfficeOfReportingEntity,ReportingPeriodEndDate,ReportingPeriodStartDate,SignatureOfAuditorsDate,SignatureOfAuditorsPlace,StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements,StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements,TelephoneNumberOfAuditor,TelephoneNumberOfReportingEntity,_id,_index,_score,cvrNummer,indlaesningsId,indlaesningsTidspunkt,offentliggoerelsesTidspunkt,offentliggoerelsestype,omgoerelse,regNummer,regnskabsperiode_slutDato,regnskabsperiode_startDato,sagsNummer,sidstOpdateret,ProfitLoss,AdjustmentsForCurrentTaxOfPriorPeriod,AdjustmentsForDeferredTax,AdministrativeExpenses,AmortisationOfIntangibleAssets,AverageNumberOfEmployees,CostOfProduction,DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss,DepreciationOfPropertyPlantAndEquipment,EmployeeBenefitsExpense,EquityRatio,FeesForAuditorsPerformingStatutoryAudit,FeesForAuditorsPerformingTaxConsultancy,FeesForOtherServicesPerformedByAuditors,GrossMargin,GrossProfitLoss,InterestExpenseAssignedToGroupEnterprises,InterestIncomeFromGroupEnterprises,InvestmentInPropertyPlantAndEquipment,OperatingMargin,OtherAdjustmentsOfFinanceExpenses,OtherAdjustmentsOfFinanceIncome,OtherFinanceExpenses,OtherFinanceIncome,OtherOperatingExpenses,PostemploymentBenefitExpense,ProfitLossFromOrdinaryActivitiesBeforeTax,ProfitLossFromOrdinaryOperatingActivities,ResultsFromNetFinancials,ReturnOnCapitalEmployed,ReturnOnEquity,Revenue,SocialSecurityContributions,TaxExpenseOnOrdinaryActivities,WagesAndSalaries,NominalValueOfIssuedShares,AcquiredIntangibleAssets,Assets,CashAndCashEquivalents,ContributedCapital,CurrentAssets,FixturesFittingsToolsAndEquipment,IntangibleAssets,LandAndBuildings,LiabilitiesAndEquity,LiabilitiesOtherThanProvisions,LongtermInvestmentsAndReceivables,NoncurrentAssets,OtherAccruedExpenses,OtherLongtermReceivables,OtherShorttermPayables,OtherShorttermReceivables,PropertyPlantAndEquipment,PropertyPlantAndEquipmentInProgress,Provisions,ProvisionsForDeferredTax,RetainedEarnings,ShorttermLiabilitiesOtherThanProvisions,ShorttermPayablesToGroupEnterprises,ShorttermReceivables,ShorttermReceivablesFromGroupEnterprises,ShorttermTaxReceivables,ShorttermTradePayables,AccumulatedImpairmentLossesAndAmortisationOfIntangibleAssets,IntangibleAssetsGross,AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment,PropertyPlantAndEquipmentGross,NameAndSurnameOfAuditor,NameOfAuditFirm,DescriptionOfAuditor,AdditionsToPropertyPlantAndEquipment,DisposalsOfPropertyPlantAndEquipment,IncreaseDecreaseOfPropertyPlantAndEquipmentThroughTransfers,ReversalsOfImpairmentLossesAndDepreciationOfDisposedPropertyPlantAndEquipment,NameAndSurnameOfMemberOfSupervisoryBoard,DescriptionOfClassOfIssuedShares,NumberOfIssuedShares
26060702,2012-01-01,2012-01-01,c309,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",390000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2012-01-01,2012-01-01,c354,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",3462208000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2012-01-01,2012-12-31,c195,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,49803000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2012-01-01,2012-12-31,c355,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,49803000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2012-01-01,2012-12-31,c433,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,49803000.0,0.0,16674000.0,68511000.0,3121000.0,375.0,514997000.0,117721000.0,114600000.0,270587000.0,93.3,1022000.0,30000.0,22000.0,22.1,145827000.0,1133000.0,43000.0,193567000.0,10.0,36000.0,1746000.0,1169000.0,1789000.0,11459000.0,18885000.0,66477000.0,65857000.0,620000.0,1.8,1.4,660824000.0,3522000.0,16674000.0,248180000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2012-12-31,2012-12-31,c1294,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,385000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2012-12-31,2012-12-31,c1296,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2012-12-31,2012-12-31,c5,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",3512401000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5474000.0,3763370000.0,5931000.0,390000.0,230905000.0,1361801000.0,5474000.0,2023031000.0,3763370000.0,215126000.0,313000.0,3532465000.0,71853000.0,313000.0,71853000.0,1535000.0,3526678000.0,141846000.0,35843000.0,35843000.0,3512011000.0,215126000.0,78112000.0,224974000.0,197131000.0,26308000.0,65161000.0,,,,,,,,,,,,,,
26060702,2013-01-01,2013-01-01,c136,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15416000.0,20890000.0,,,,,,,,,,,,
26060702,2013-01-01,2013-01-01,c217,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,259141000.0,2282172000.0,,,,,,,,,,
26060702,2013-01-01,2013-01-01,c235,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,159897000.0,1521700000.0,,,,,,,,,,
26060702,2013-01-01,2013-01-01,c246,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,141845000.0,,,,,,,,,,
26060702,2013-01-01,2013-01-01,c312,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",390000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-01-01,c351,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",3512011000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,c1,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,102686000.0,-2291000.0,28322000.0,78567000.0,938000.0,483.0,839085000.0,195100000.0,194162000.0,415894000.0,91.8,1092000.0,0.0,0.0,20.4,215045000.0,401000.0,89000.0,165635000.0,12.9,9962000.0,3385000.0,10363000.0,3474000.0,872000.0,26701000.0,128717000.0,135606000.0,-6889000.0,3.6,2.9,1054130000.0,4703000.0,26031000.0,384490000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Torben Jensen,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,,,,,,,,
26060702,2013-01-01,2013-12-31,c105,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rikke Lund-KÃ¼hl,,state authorised public accountant,,,,,,,
26060702,2013-01-01,2013-12-31,c106,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Torben Jensen,,state authorised public accountant,,,,,,,
26060702,2013-01-01,2013-12-31,c137,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,938000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,c194,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,102686000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,c222,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,89150000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,34978000.0,0.0,,,
26060702,2013-01-01,2013-12-31,c236,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,105012000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,-36333000.0,56219000.0,-3931000.0,,,
26060702,2013-01-01,2013-12-31,c247,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,165635000.0,-288000.0,-93146000.0,0.0,,,
26060702,2013-01-01,2013-12-31,c33,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inga Birgitte Thygesen,,
26060702,2013-01-01,2013-12-31,c352,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,102686000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,c435,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,41103000.0,,,,,200.0,,,,,96.5,,,,22.4,,,,144528000.0,12.1,,,,,,,,45576000.0,6226000.0,1.2,1.2,377812000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,c438,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,35956000.0,,,,,209.0,,,,,95.1,,,,25.3,,,,70124000.0,10.6,,,,,,,,38719000.0,12381000.0,1.0,1.0,365467000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,c441,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,96757000.0,,,,,230.0,,,,,96.5,,,,44.6,,,,110724000.0,28.0,,,,,,,,126445000.0,3353000.0,3.1,2.5,452376000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,c49,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Esther Maria Alegria,,
26060702,2013-01-01,2013-12-31,c50,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Stober,,
26060702,2013-01-01,2013-12-31,c72,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A,
26060702,2013-01-01,2013-12-31,c73,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,B,
26060702,2013-01-01,2013-12-31,c76,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-12-31,2013-12-31,c138,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6485000.0,,,,,,,,,,,,,,,,,,,,,16354000.0,22839000.0,,,,,,,,,,,,
26060702,2013-12-31,2013-12-31,c223,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1968859000.0,,,,,,,,,,,,,348291000.0,2317150000.0,,,,,,,,,,
26060702,2013-12-31,2013-12-31,c237,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1280608000.0,,,,,,,,,,,,,260978000.0,1541586000.0,,,,,,,,,,
26060702,2013-12-31,2013-12-31,c248,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,214046000.0,,,,,,,,,,,,,0.0,214046000.0,,,,,,,,,,
26060702,2013-12-31,2013-12-31,c314,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",390000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-12-31,2013-12-31,c353,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",3471697000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-12-31,2013-12-31,c437,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",3462587000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3586870000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-12-31,2013-12-31,c440,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",3606484000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3791171000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-12-31,2013-12-31,c443,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",3570528000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3699798000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-12-31,2013-12-31,c68,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,385000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3850.0
26060702,2013-12-31,2013-12-31,c69,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0
26060702,2013-12-31,2013-12-31,c7,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8vcGRmcy8yNjA2MDcwMjtBcFMyODYyNzk7MjAxMzAxMDE7MjAxMzEyMzE7UjtS.pdf,http://regnskaber.virk.dk/20706062/Y3ZyLmRrOi8veGJybHMvWC1DRkFDRDJFNi0yMDE0MDUxNV8xNzIwMzlfMzEw.xml,Danmark,2900 Hellerup,Strandvejen 44,3400  HillerÃ¸d,Biogen Idec AllÃ© 1,2860 SÃ¸borg,Gyngemose Parkvej 50,To the shareholders of Biogen Idec (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2013 and of the results of the company's operations for the financial year 1 January - 31 December 2013.",2014-05-12,2014-05-12,2014-05-12,chairman,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash comprises cash balances and bank balances.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of biotechnological products.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 182,851 and Administrative expenses with t.kr. 12,249.","Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.",3472087000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Idec Inc.",The accounting policies applied by the company are consistent with those of last year.,-143000000.0,77416070.0,www.biogenidec.dk,26060702.0,26052394.0,"Today, management has discussed and approved the annual report of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2013.","We have audited the financial statements of Biogen Idec (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2013, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.",1949000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen Idec (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"In our opinion, the management's review includes a fair review of the matters dealt with in the management's review.",Kaare Smit,Andrew Stober,Biogen Idec (Denmark),Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 December 2013 and of the results of the company operations for the financial year 1 January - 31 December 2013 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2013-12-31,2013-01-01,2014-05-12,"Copenhagen,","Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.","We have read management's review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the financial statements. On this basis, in our opinion, the information provided in management's review is consistent with the financial statements.",+45 39 45 39 45,77416000.0,urn:ofk:oid:12770819,indberetninger-20180424,2.5097342,26060702.0,,2018-03-31T21:10:05.799Z,2014-05-15T22:00:00.000Z,regnskab,0.0,,2013-12-31,2013-01-01,14-52.268,2014-05-15T22:00:00.000Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6485000.0,3784036000.0,71795000.0,390000.0,314038000.0,1280608000.0,6485000.0,1968859000.0,3784036000.0,247784000.0,0.0,3469998000.0,123447000.0,0.0,123447000.0,2385000.0,3463513000.0,214046000.0,64165000.0,64165000.0,3471697000.0,247784000.0,17090000.0,242243000.0,239858000.0,0.0,107247000.0,,,,,,,,,,,,,,
